Turning Point Therapeutics, Inc.
TPTXDelisted Aug 17, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595893
Turning Point Therapeutics, Inc. was delisted on Aug 17, 2022; its insiders filed their last Form 4 on Aug 17, 2022; 209 institutions reported holding it in 13F filings for Q2 2022, worth $3.29B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 209
- Q2 2022, +58 vs. previous quarter
- 13F value
- $3.29B
- Reported value at the end of Q2 2022
- Superinvestors holding
- 1
- At the end of Q2 2022
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2021
- $30.8M
- +23.3% year over year
- Net income, FY2021
- -$236.6M
- No comparable prior period
- Free cash flow, FY2021
- -$156.3M
- No comparable prior period
- Revenue, Q2 FY2022
- $119.0K
- −97.7% year over year
Revenue flow, FY2021
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2021: $236.6M (767.3% of revenue).
Superinvestors holding TPTX, Q2 2022
Go to the superinvestors tab1 superinvestor reports holding Turning Point Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
1.2%
Turning Point Therapeutics, Inc.'s share of the portfolio
- Shares
- 821,635
- Value
- $61.8M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Turning Point Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 29, 2022 (view filing) | Jul 27 | 2 days | Tombesi PaoloEVP & Chief Financial Officer | SSale | −1.18K | $74.94 | −$88.7K | −4.0%28.7K after | |
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | Reich SiegfriedEVP & Chief Scientific Officer | SSale | −397 | $36.30 | −$14.4K | −10.3%3.45K after | |
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | Partridge Andrew JohnEVP & Chief Commercial Officer | SSale | −221 | $36.30 | −$8.02K | −1.0%22.1K after | |
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | North AnnetteEVP & General Counsel | SSale | −669 | $36.30 | −$24.3K | −5.4%11.7K after | |
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | Hirmand MohammadEVP & Chief Medical Officer | SSale | −669 | $36.30 | −$24.3K | −8.9%6.84K after | |
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | Countouriotis AthenaPresident & CEO | SSale | −2.97K | $36.30 | −$107.8K | −5.8%47.9K after | |
| Aug 31, 2021 (view filing) | Aug 30 | 1 day | North AnnetteEVP, General Counsel & Secty. | SSale | −10.0K | $80.00 | −$800.0K | −44.7%12.4K after | |
| Jul 15, 2021 (view filing) | Jul 14 | 1 day | Partridge Andrew JohnEVP & Chief Commercial Officer | SSale | −1.87K | $74.90 | −$140.0K | −7.9%21.8K after |
Top 10 13F holders, Q2 2022
See all 209 holdersThe largest institutional positions in Turning Point Therapeutics, Inc. at the end of Q2 2022; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 4,157,552 | $312.9M | 0.01% | +244,424+6.2% | Added |
| BlackRock Inc. | 3,791,801 | $285.3M | 0.01% | +99,587+2.7% | Added |
| Cormorant Asset Management, LP | 2,484,220 | $186.9M | 14.50% | −1,215,780−32.9% | Reduced |
| OrbiMed Advisors LLC | 2,012,250 | $151.4M | 2.94% | −6,700−0.3% | Reduced |
| Wellington Management Group LLP | 1,910,170 | $143.7M | 0.03% | −2,120,821−52.6% | Reduced |
| State Street Corp | 1,650,689 | $124.2M | 0.01% | −1,469,237−47.1% | Reduced |
| FIL Ltd | 1,163,475 | $87.6M | 0.10% | +1,163,475 | New |
| Farallon Capital Management, L.L.C. | 1,160,000 | $87.3M | 0.51% | +1,160,000 | New |
| Alpine Associates Management Inc. | 1,028,400 | $77.4M | 2.91% | +1,028,400 | New |
| Price T Rowe Associates Inc | 953,914 | $71.8M | 0.01% | −3,008,738−75.9% | Reduced |